TAKE Solutions Ltd Q2 FY26 – From Life Sciences to Life Support: The Curious Case of Vanishing Promoters and Zero Sales
1. At a Glance
Once hailed as a tech-powered life sciences play, TAKE Solutions now looks like a clinical trial gone horribly wrong. At ₹21.7 a share (as of Oct 31, 2025), this ₹320 crore market-cap wonder has somehow managed to show zero quarterly sales and a ₹0.63 crore loss — but still sports a P/E of 80.3. Don’t ask how. Even Newton would’ve quit finance.
The company that once ran global drug trials is now trialing its investors’ patience. ROE? A meme-worthy 644%, because when your net worth is microscopic and you accidentally make ₹4 crore profit, the math just explodes. Promoter holding? Down from 53% to 5.19% — a corporate version of a magician vanishing act.
The cherry on this chaotic cake: auditors resigned mid-year, citing “fee disagreements,” and the board meeting note mentions “going concern doubts.” This isn’t a company report; it’s an obituary in slow motion.
2. Introduction – When the Lab Runs Out of Test Subjects
Once upon a fiscal year, TAKE Solutions was a global name in clinical research. Headquartered in Chennai, listed in India, run from Singapore — this was the desi dream of “Biotech meets IT.” Their subsidiaries in the U.S., Thailand, and Singapore ran drug trials, pharmacovigilance, and regulatory filings for global pharma giants.
Then came 2022: lenders forced the sale of TAKE’s crown jewel subsidiary, TAKE Ghapte (Singapore). The forced disinvestment nuked the company’s revenue stream, leaving only fragments of its once-buzzing operations.
By FY25, the company reported literally zero operational revenue, negative net worth until FY24, and was surviving on “other income” (read: interest, scraps, and divine luck). The promoter group kept selling shares faster than you could say “insider disclosure.”
Now, in FY26, TAKE stands as a ghost of its former self — no business, no promoters, just filings. If this were a movie, it would be titled: “TAKE: Endgame – The Disintegration.”
3. Business Model – WTF Do They Even Do (Anymore)?
Originally, TAKE Solutions offered:
Life Sciences: Clinical trials, pharmacovigilance, bioavailability and bioequivalence studies, and regulatory filing.
Supply Chain Management: IT-based logistics and analytics for pharma operations.
That was the past tense.
Post-2022, after the fire sale of its subsidiaries (TAKE Ghapte, Acunova, Navitas Thailand), the company’s operational backbone vanished. What remains today is mainly Ecron Acunova Ltd, focused on bioequivalence studies and small-scale clinical trials in India, particularly at Manipal — where they’re expanding a 150-bed facility (costing ₹12 crore).
They also incorporated TAKE Consultancy Services Inc. (USA) — perhaps to keep one corporate foot in the U.S., though it’s unclear if it’s anything more than a mailbox.
So, what’s the business model now? Imagine a hospital that lost all its doctors but kept the reception desk running — technically “open,” but operationally empty.
4. Financials Overview
Source table
Metric
Q2 FY26 (Sep 2025)
Q2 FY25 (Sep 2024)
Q1 FY26 (Jun 2025)
YoY %
QoQ %
Revenue
₹0.00 Cr
₹0.00 Cr
₹0.00 Cr
—
—
EBITDA
-₹0.30 Cr
-₹0.90 Cr
-₹0.44 Cr
—
32%
PAT
₹6.29 Cr
-₹1.58 Cr
-₹0.91 Cr
—
—
EPS (₹)
0.43
-0.11
-0.06
—
—
💬 Commentary: Revenue: zero. PAT: positive. Logic: none. TAKE’s P&L is a classic example of how “other income” (₹6.92 crore this quarter) can give artificial life to a company otherwise clinically dead. The 53% QoQ profit “growth” is just a rebound from last quarter’s negative base — not an operational turnaround.
5. Valuation Discussion – Fair Value Range (aka: Why Does This Even Trade?)
Let’s do the math, humor included:
a) P/E Method: EPS = ₹3.26. But remember: there’s no sales and no business. Still, with industry P/E ≈ 45, the “hope value” puts this around ₹15–₹25.
b) EV/EBITDA Method: EV = ₹320 Cr, EBITDA ≈ ₹5.5 Cr (all from “other income”). → EV/EBITDA = 58x (industry average = 10–15x). → Fair Value Range: ₹5–₹12 (based on adjusted EBITDA).
c) DCF (Dreamer’s Cash Flow): If they somehow restart operations generating ₹25 Cr/year growing 10%, discounted at 12%, you get ₹50–₹60 Cr enterprise value. → ~₹10–₹12/share again.
🎓 Educational Fair Value Range: ₹5 – ₹25 per share. CMP ₹21.7
